NYSE:LLY 21 December 2025 - 29 December 2025

Eli Lilly and Company stock is in the spotlight on December 24, 2025 as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise. In a shortened U.S. trading session—with NYSE and Nasdaq closing early at 1:00 p.m. ET—LLY shares traded modestly higher in morning action, with lighter volume typical of holiday weeks. New York Stock Exchange+1

Novo Nordisk A/S is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2 The approval also lands at a delicate moment for Novo: competition from Eli Lilly has intensified, pricing pressure is building, and investors have been scrutinizing Novo’s growth outlook and execution. Today’s FDA decision doesn’t erase those issues—but it changes the chessboard for 2026. Reuters+1